Cargando…

Cancer Vaccines Based on Fluorine-Modified KH-1 Elicit Robust Immune Response

KH-1 is a tumor-associated carbohydrate antigen (TACA), which serves as a valuable target of antitumor vaccines for cancer immunotherapies. However, most TACAs are thymus-independent antigens (TD-Ag), and they tend to induce immunological tolerance, leading to their low immunogenicity. To overcome t...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Li, Bohan, Zheng, Xiujing, Xiong, Decai, Ye, Xinshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963332/
https://www.ncbi.nlm.nih.gov/pubmed/36838925
http://dx.doi.org/10.3390/molecules28041934
_version_ 1784896227159048192
author Liu, Yang
Li, Bohan
Zheng, Xiujing
Xiong, Decai
Ye, Xinshan
author_facet Liu, Yang
Li, Bohan
Zheng, Xiujing
Xiong, Decai
Ye, Xinshan
author_sort Liu, Yang
collection PubMed
description KH-1 is a tumor-associated carbohydrate antigen (TACA), which serves as a valuable target of antitumor vaccines for cancer immunotherapies. However, most TACAs are thymus-independent antigens (TD-Ag), and they tend to induce immunological tolerance, leading to their low immunogenicity. To overcome these problems, some fluorinated derivatives of the KH-1 antigen were designed, synthesized, and conjugated to the carrier protein CRM197 to form glycoconjugates, which were used for immunological studies with Freund’s adjuvant. The results showed that fluorine-modified N-acyl KH-1 conjugates can induce higher titers of antibodies, especially IgG, which can recognize KH-1-positive cancer cells and can eliminate cancer cells through complement-dependent cytotoxicity (CDC). The trifluoro-modified KH-1-TF-CRM197 showed great potential as an anticancer vaccine candidate.
format Online
Article
Text
id pubmed-9963332
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99633322023-02-26 Cancer Vaccines Based on Fluorine-Modified KH-1 Elicit Robust Immune Response Liu, Yang Li, Bohan Zheng, Xiujing Xiong, Decai Ye, Xinshan Molecules Article KH-1 is a tumor-associated carbohydrate antigen (TACA), which serves as a valuable target of antitumor vaccines for cancer immunotherapies. However, most TACAs are thymus-independent antigens (TD-Ag), and they tend to induce immunological tolerance, leading to their low immunogenicity. To overcome these problems, some fluorinated derivatives of the KH-1 antigen were designed, synthesized, and conjugated to the carrier protein CRM197 to form glycoconjugates, which were used for immunological studies with Freund’s adjuvant. The results showed that fluorine-modified N-acyl KH-1 conjugates can induce higher titers of antibodies, especially IgG, which can recognize KH-1-positive cancer cells and can eliminate cancer cells through complement-dependent cytotoxicity (CDC). The trifluoro-modified KH-1-TF-CRM197 showed great potential as an anticancer vaccine candidate. MDPI 2023-02-17 /pmc/articles/PMC9963332/ /pubmed/36838925 http://dx.doi.org/10.3390/molecules28041934 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Yang
Li, Bohan
Zheng, Xiujing
Xiong, Decai
Ye, Xinshan
Cancer Vaccines Based on Fluorine-Modified KH-1 Elicit Robust Immune Response
title Cancer Vaccines Based on Fluorine-Modified KH-1 Elicit Robust Immune Response
title_full Cancer Vaccines Based on Fluorine-Modified KH-1 Elicit Robust Immune Response
title_fullStr Cancer Vaccines Based on Fluorine-Modified KH-1 Elicit Robust Immune Response
title_full_unstemmed Cancer Vaccines Based on Fluorine-Modified KH-1 Elicit Robust Immune Response
title_short Cancer Vaccines Based on Fluorine-Modified KH-1 Elicit Robust Immune Response
title_sort cancer vaccines based on fluorine-modified kh-1 elicit robust immune response
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963332/
https://www.ncbi.nlm.nih.gov/pubmed/36838925
http://dx.doi.org/10.3390/molecules28041934
work_keys_str_mv AT liuyang cancervaccinesbasedonfluorinemodifiedkh1elicitrobustimmuneresponse
AT libohan cancervaccinesbasedonfluorinemodifiedkh1elicitrobustimmuneresponse
AT zhengxiujing cancervaccinesbasedonfluorinemodifiedkh1elicitrobustimmuneresponse
AT xiongdecai cancervaccinesbasedonfluorinemodifiedkh1elicitrobustimmuneresponse
AT yexinshan cancervaccinesbasedonfluorinemodifiedkh1elicitrobustimmuneresponse